ABSTRACT
Amputation and chemotherapy are the mainstay of treatment for canine appendicular osteosarcoma (OSA). In vitro studies have demonstrated anti-tumour activity of pamidronate against canine OSA. The purpose of this study was to assess the safety of adding pamidronate to standard post-operative carboplatin chemotherapy in 17 dogs with appendicular OSA treated with limb amputation. Median disease-free interval (DFI) and median survival time (MST) were evaluated as secondary endpoints. Incidence of side effects and treatment outcomes were compared to 14 contemporary control patients treated with carboplatin alone. There were no identified side effects to the pamidronate treatment. The median DFI for the study group was 185 days compared to 172 days for the control group (P = 0.90). The MST of the study group was 311 days compared to 294 days for the control group (P = 0.89). Addition of pamidronate to carboplatin chemotherapy for the treatment of canine appendicular OSA is safe and does not impair efficacy of standard carboplatin treatment.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/veterinary , Carboplatin/administration & dosage , Diphosphonates/administration & dosage , Dog Diseases/drug therapy , Osteosarcoma/veterinary , Amputation, Surgical/veterinary , Animals , Antineoplastic Agents/administration & dosage , Bone Neoplasms/drug therapy , Bone Neoplasms/surgery , Bones of Lower Extremity/pathology , Chemotherapy, Adjuvant , Disease-Free Survival , Dog Diseases/surgery , Dogs , Female , Kaplan-Meier Estimate , Male , Osteosarcoma/drug therapy , Osteosarcoma/surgery , Pamidronate , Prospective Studies , Schools, Veterinary , WisconsinABSTRACT
We examined the presence of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) abnormalities that could contribute to the origin or progression of naturally occurring canine endothelial tumors (hemangiosarcoma). Our results document somatic point mutations or deletions encompassing the PTEN C-terminal domain in canine hemangiosarcoma that might provide cells a survival advantage within their microenvironment. This represents the first characterization of a naturally occurring, highly metastatic tumor with biologically significant mutations of PTEN in the C-terminal domain.
